The treatment landscape of breast cancer has been greatly changed by the innovative targeting therapies. Antibody-drug conjugates (ADCs) with a representative of trastuzumab deruxtecan (T-DXd) are the most successful ones. The revolutionary next-generation design of ADC transformed to the unprecedented clinical data. T-DXd has been evaluated as treatment of several HER2-expressing cancers, including HER2-positive and HER2-low breast cancer. This is the first HER2-targeted therapy active for HER2-low breast cancer.
In this review we focus on efficacy and toxicity profile of this novel anti-HER2 compound, and provide an update on the most recent results of ongoing clinical trials of T-DXd.
台灣第一三共股份有限公司
成為致力於社會永續發展創新型全球醫療保健公司
為實現我們存在的意義，第一三共集團致力於透過業務活動解決社會期望我們解決的社會問題，例如研發創新的藥品以及努力實現SDGs永續發展目標。我們將發揮我們擅長的科學與技術，持續地挑戰以提供創新的解決方案。
臺灣阿斯特捷利康股份有限公司
以領先科學聞名的全球生物製藥公司 – 阿斯特捷利康，致力於處方藥物的研究發展與醫療用途，並專注於三大治療領域：腫瘤、心血管腎臟代謝、呼吸道與免疫。阿斯特捷利康積極拓展全球超過100個國家市場，全球逾數百萬患者都曾受惠於其創新藥物